Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CINRYZE Donor Pre-treatment in High KDPI Kidney Transplants
NCT02435732Phase 1Unknown
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of c1-esterase inhibitor in delayed graft function (DGF) (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement at 12 months. Status: unknown.
02
Drugs
c1-esterase inhibitor
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02435732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435732.